Ronnie Andrews joined OncoCyte as CEO in July 2019. Prior to this, Ronnie was the founder and principal of the Bethesda Group LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies move emerging diagnostic content and platforms into the marketplace. Ronnie has close to 30 years of experience in the US Clinical and Molecular Diagnostics industry. He served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. Prior to this Ronnie held a number of other high-profile executive roles including CEO of Clarient, a public company on the NASDAQ which was sold to General Electric Healthcare in 2010.
Adjuvant chemotherapy is a common treatment approach for various cancers. Understanding and discriminating patients which would benefit from adjuvant chemotherapy has a significant impact on patient outcome and survival rate. This panel discussion - using the example of thoracic surgery with a thoracic surgeon, oncologist, and radiation oncologist present - will touch upon how precision oncology applied to thoracic surgery is optimizing decision-making, where some of the challenges reside that need to be overcome, and lastly how the thoracic cancer model can be applied to other cancer types.